Mely combines validated cognitive testing with advanced machine learning to generate digital biomarkers that enable early diagnosis of neurodegenerative diseases — at scale, with clinical-grade security.
A seamless, secure pipeline that transforms patient test data into clinically actionable digital biomarkers.
Standardised cognitive and motor tests are administered digitally through our validated assessment platform — non-invasive and completed in minutes.
Raw test data is encrypted end-to-end and stored in our GDPR & HIPAA compliant infrastructure — immutable, auditable, and fully anonymised.
Proprietary machine learning models analyse multi-dimensional patient data, detecting subtle patterns invisible to the human eye across thousands of data points.
Digital biomarkers are extracted, validated, and scored — quantitative signatures that objectively measure neurological function across multiple disease axes.
Clinicians receive structured, interpretable reports with early-stage risk indicators — enabling intervention years before conventional diagnostic thresholds are reached.
Every component of the Mely platform is designed with clinical rigour, scientific validity, and enterprise-grade security.
Scientifically validated cognitive and motor tests delivered via an intuitive digital interface. Tests capture fine-grained temporal, kinematic, and cognitive performance data that standard clinical assessments miss.
End-to-end encrypted data pipeline from device to storage. Raw data is anonymised at the point of capture and stored in compliance-ready infrastructure.
Proprietary ML models trained on longitudinal cohort data. Continuously improved with new validated patient data from clinical partners.
Multi-dimensional biomarker extraction and validation framework. Each biomarker is clinically validated against gold-standard diagnostic outcomes.
Mely's platform provides distinct value across the neurology ecosystem.
Receive objective, quantitative early-warning indicators that complement clinical judgment. Identify at-risk patients years before conventional diagnostic thresholds, enabling earlier intervention and better patient outcomes.
Access longitudinal, multi-modal datasets and pre-validated digital biomarkers for research into disease mechanisms, progression, and therapeutic targets. Accelerate discovery with ready-to-analyse structured data.
Leverage validated digital endpoints for clinical trial design and patient stratification. Reduce trial costs by identifying eligible patients earlier and tracking disease progression with high-resolution, objective biomarkers.
Episodic memory, semantic fluency, and executive function biomarkers.
Motor, tremor kinematic, and gait-based digital biomarkers.
Cognitive processing speed and fine-motor coordination biomarkers.
Speech fluency, motor response latency, and grip strength biomarkers.
Patient data is the foundation of what we do. Every layer of our infrastructure is built around protecting it — by default, not as an afterthought.
Full compliance with European data protection regulations. Data minimisation, right to erasure, and consent management built in.
Technical and administrative safeguards meeting US HIPAA standards for protected health information.
Information security management aligned with ISO 27001 international standard — systematic approach to protecting sensitive data.
AES-256 encryption at rest, TLS 1.3 in transit. Data is encrypted at the point of capture and never stored in plain text.
Immutable, timestamped audit logs for all data access and processing operations — enabling full regulatory traceability.
Patient identifiers are decoupled at ingestion. Analytical pipelines operate exclusively on pseudonymised or anonymised data.
Neurodegenerative diseases are among the most challenging conditions in medicine. By the time symptoms are clinically apparent, significant neurological damage has already occurred — and the window for meaningful intervention has narrowed.
Mely was founded with a singular mission: to push the diagnostic boundary earlier. By combining sensitive digital tests with machine learning, we can detect the subtle signatures of disease years before they manifest clinically — giving patients, families, and clinicians more time to act.
We are a team of engineers, data scientists, neuroscientists, and clinicians united by the belief that data — collected carefully, analysed rigorously, and protected absolutely — can change outcomes.
Whether you're a clinician, researcher, or industry partner — we'd love to explore how Mely can support your work.
Interested in integrating Mely's biomarker platform into your clinical or research workflow? Let's talk.
We actively collaborate with academic institutions and research centres. Reach out to discuss data access and joint studies.
For media inquiries, interview requests, or press materials, please use the contact form.